Reply

Arthritis Care and Research

Volumn 65, Issue 5, 2013, Pages 832-833

  Singh, Jasvinder A ^a   Saag, Kenneth G ^a   Furst, Daniel ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR;

DISEASE ACTIVITY; DRUG COST; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; LETTER; META ANALYSIS (TOPIC); PATIENT COMFORT; PATIENT PREFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RHEUMATOLOGY;

EID: 84876712040     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21872     Document Type: Letter

References (4)

1. Graudal N, Jurgens G,. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta- analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 2010; 62: 2852-63.
2. Ma MH, Kingsley GH, Scott DL,. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2010; 49: 91-8.
3. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
4. Yazdany J, Schmajuk G, Robbins M, Daikh D, Beall A, Yelin E, et al, and the American College of Rheumatology Core Membership Group. Choosing Wisely: the American College of Rheumatology's top 5 list of things physicians and patients should question. Arthritis Care Res (Hoboken) 2013; 65: 329-39.